HHS Announces $90M Partnership For Anti-Bioterrorism Drug

Law360, Washington (February 5, 2014, 7:26 PM EST) -- The U.S. Department of Health and Human Services will provide up to $90 million through a public-private partnership with a unit of The Medicines Co. for the development of a drug designed to treat antibiotic-resistant infections and protect against bioterrorism threats, it announced Wednesday.

Under the terms of the cost-sharing deal, the Biomedical Advanced Research and Development Authority, or BARDA — which serves under HHS’ Office of the Assistant Secretary for Preparedness and Response — will support the development of San Diego-based Rempex Pharmaceuticals Inc.’s Carbavance....
To view the full article, register now.